--- title: "NewAmsterdam Pharma Company (NAMS) stock and investor profile" url: "https://aibio.space/companies/newamsterdam-pharma-n-v/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS), Netherlands. The directory classifies it as Pharmaceuticals: Major." --- NAMS NewAmsterdam Pharma Company N.V. NASDAQ · Netherlands # NewAmsterdam Pharma Company (NAMS) news Top story · Aug 14, 2026 · SEC filing 8-K ## [NewAmsterdam Pharma N.V. reports a leadership change](https://www.sec.gov/Archives/edgar/data/1936258/000119312526352186/nams-20260810.htm) Gunning succeeds Louise Kooij, whose departure from the Company effective August 31, 2026, was previously announced, in such capacity. Source: [8-K filed Aug 14, 2026 on SEC EDGAR](https://www.sec.gov/Archives/edgar/data/1936258/000119312526352186/nams-20260810.htm) ## Latest NewAmsterdam Pharma Company news We have not published a story on NewAmsterdam Pharma Company yet. When there is news, it will appear here. ## NewAmsterdam Pharma Company at a glance - **Ticker**: NAMS - **Listing**: NASDAQ - **Country**: Netherlands - **Cash, Jun 30, 2026**: $633.9 million ### Related companies - [Pharming Group NV](https://aibio.space/companies/pharming/) EURONEXT: PHARM - [ProQR Therapeutics](https://aibio.space/companies/proqr-therapeutics-n-v/) NASDAQ: PRQR - [Pharvaris](https://aibio.space/companies/pharvaris-n-v/) NASDAQ: PHVS - [argenx](https://aibio.space/companies/argenx/) EURONEXT: ARGX - [uniQure](https://aibio.space/companies/uniqure-n-v/) NASDAQ: QURE ### Also on NASDAQ - [Champions Oncology](https://aibio.space/companies/champions-oncology/) CSBR - [Polyrizon](https://aibio.space/companies/polyrizon/) PLRZ - [Prenetics Global](https://aibio.space/companies/prenetics-global/) PRE - [Upstream Bio](https://aibio.space/companies/upstream-bio/) UPB - [PHIBRO ANIMAL HEALTH CORP](https://aibio.space/companies/phibro-animal-health/) PAHC - [Cognition Therapeutics](https://aibio.space/companies/cognition-therapeutics/) CGTX ## NewAmsterdam Pharma Company annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$22.5 million](https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/) | [$45.6 million](https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/) | | Research and development | [$141.8 million](https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/) | [$151.4 million](https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/) | | Net income (loss) | [-$203.8 million](https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/) | [-$241.6 million](https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/) | | Cash from operations | [-$147.8 million](https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/) | [-$158.6 million](https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/) | | Cash and equivalents | [$490.0 million](https://www.sec.gov/Archives/edgar/data/1936258/000119312526333824/) | [$771.7 million](https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/) | | Short-term investments | [$146.2 million](https://www.sec.gov/Archives/edgar/data/1936258/000119312526333824/) | [$62.4 million](https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $424.2 million, plus short-term investments of $209.7 million, $633.9 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about NewAmsterdam Pharma Company What is the ticker symbol of NewAmsterdam Pharma Company? NewAmsterdam Pharma Company N.V. trades under the ticker NAMS on NASDAQ. Where is NewAmsterdam Pharma Company listed? NewAmsterdam Pharma Company N.V. is listed on NASDAQ. Our directory also records these other listings: GETTEX:KH6; LS:A3DUAC; LSX:A3DUAC. What is the SEC CIK of NewAmsterdam Pharma Company? The SEC Central Index Key (CIK) for NewAmsterdam Pharma Company N.V. is 1936258. Its filings are on SEC EDGAR. How many shares does NewAmsterdam Pharma Company have outstanding? 119,537,169 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-05. Which country or territory is NewAmsterdam Pharma Company listed under? Our directory records NewAmsterdam Pharma Company N.V. under Netherlands. What does NewAmsterdam Pharma Company do? Our directory classifies NewAmsterdam Pharma Company N.V. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of NewAmsterdam Pharma Company? The ISIN recorded for NewAmsterdam Pharma Company N.V. is NL00150012L7. Does aibio.space cover NewAmsterdam Pharma Company? aibio.space lists NewAmsterdam Pharma Company N.V. among 2,820 public biotech companies and publishes its news here as stories appear. Where is NewAmsterdam Pharma Company incorporated? SEC records list its state or country of incorporation as P7. What was NewAmsterdam Pharma Company's revenue last year? $22.5 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is NewAmsterdam Pharma Company profitable? NewAmsterdam Pharma Company N.V. reported a net loss of $203.8 million for the fiscal year ended Dec 31, 2025, and used $147.8 million of cash in operations, per its annual report to the SEC. How much does NewAmsterdam Pharma Company spend on research and development? $141.8 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does NewAmsterdam Pharma Company have? $633.9 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is NewAmsterdam Pharma Company's market cap? We do not publish live share prices. In its annual report, NewAmsterdam Pharma Company N.V. put the market value of shares held by non-affiliates (public float) at $1.35 billion as of Jun 30, 2025. Is NewAmsterdam Pharma Company a smaller reporting company? SEC records list NewAmsterdam Pharma Company N.V.'s filer category as: Large accelerated filer. ## Investor discussion: NewAmsterdam Pharma Company Members talk about NewAmsterdam Pharma Company (NAMS). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at NewAmsterdam Pharma Company, newest first. Each line links the filing it comes from. 1. 2024-12-10 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1936258/000119312524274386/d919275d424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NAMS on TradingView](https://www.tradingview.com/symbols/NASDAQ-NAMS/). ## SEC filings and registration - **SEC name**: NewAmsterdam Pharma Co N.V. - **CIK**: 1936258 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: NAMS (Nasdaq), NAMSW (Nasdaq) - **State or country of incorporation**: P7 - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: GOOIMEER 2-35, NARRDEN, Netherlands, 1411 DC - **Phone**: 35 206 2971 - **Shares outstanding**: 119,537,169 as of 2026-08-03 (10-Q filed 2026-08-05) - **Former names**: NewAmsterdam Pharma Co B.V. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1936258/000119312526406063/nams-20260929.htm) filed 2026-09-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1936258/000119312526396716/nams-20260921.htm) filed 2026-09-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1936258/000119312526352186/nams-20260810.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1936258/000119312526333827/nams-20260805.htm) filed 2026-08-05 - [10-Q](https://www.sec.gov/Archives/edgar/data/1936258/000119312526333824/nams-20260630.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1936258/000119312526315163/nams-20260724.htm) filed 2026-07-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1936258/000119312526312390/nams-20260716.htm) filed 2026-07-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1936258/000119312526254615/nams-20260602.htm) filed 2026-06-03 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001936258), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details NewAmsterdam Pharma Company N.V. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NAMS, recorded under Netherlands. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: NewAmsterdam Pharma Company N.V. - **Ticker**: NAMS - **Listing**: NASDAQ - **Country or territory**: Netherlands - **Business scope**: Pharmaceuticals: Major - **ISIN**: NL00150012L7 - **Other listed symbols**: GETTEX:KH6; LS:A3DUAC; LSX:A3DUAC - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-NAMS/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/newamsterdam-pharma-n-v/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "NewAmsterdam Pharma Company (NAMS) stock and investor profile", 2026-10-31, https://aibio.space/companies/newamsterdam-pharma-n-v/